ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

ATHE Alterity Therapeutics Limited

2,12
-0,075 (-3,42%)
Zuletzt aktualisiert: 20:16:23
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Alterity Therapeutics Limited ATHE NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
-0,075 -3,42% 2,12 20:16:23
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,20 2,0202 2,20 2,195
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202413:25GLOBEAppendix 4C – Q3 FY24 Quarterly Cash Flow Report
29.4.202413:25GLOBEAlterity Therapeutics Presents New Data Demonstrating..
17.4.202413:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
10.4.202413:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
26.3.202415:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
20.2.202416:25GLOBEAlterity Therapeutics to Present New Data at the Upcoming..
15.2.202423:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15.2.202423:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.2.202413:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
31.1.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.1.202413:24GLOBEAlterity Therapeutics to Participate in the ShareCafe Hidden..
22.1.202413:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
22.1.202412:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.1.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.1.202423:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.1.202423:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.1.202412:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202414:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202414:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202414:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.1.202412:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.1.202412:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.1.202414:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.1.202414:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02.1.202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.12.202314:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.12.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202314:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.12.202306:30GLOBEAlterity Therapeutics Appoints Phillip Hains as Chief..
04.12.202322:35GLOBEAlterity Therapeutics to Host Webcast to Discuss ATH434..
04.12.202313:25GLOBEAlterity Therapeutics Reports Positive Efficacy Data for..
27.11.202313:25GLOBEAlterity Therapeutics Announces Presentation of Novel..
16.11.202313:25GLOBEAlterity Therapeutics Announces Presentation of New Data..
08.11.202313:25GLOBEAlterity Therapeutics Completes Enrolment in ATH434-201..
30.10.202312:25GLOBEAppendix 4C – Q1 FY24 Quarterly Cash Flow Report
26.10.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13.9.202312:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31.8.202313:25GLOBEAlterity Therapeutics Presents New Data on Multiple System..
23.8.202313:25GLOBEAlterity Therapeutics Granted New Composition of Matter..
22.8.202313:25GLOBEAlterity Therapeutics Rare Disease Natural History Study to..
15.8.202313:25GLOBEAlterity Therapeutics Receives a $4.74 million Research &..
31.7.202313:52GLOBEAppendix 4C – Q4 FY23 Quarterly Cash Flow Report
26.7.202313:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
21.6.202313:25GLOBEAlterity Therapeutics to Present in MST Access Rare..
30.5.202313:25GLOBEAlterity Therapeutics Initiates Second Phase 2 Study in Rare..
19.5.202313:25GLOBEAlterity Therapeutics CEO David Stamler to Present at the..
10.5.202313:25GLOBEAppendix 4C – Q3 FY23 Quarterly Cash Flow Report

Kürzlich von Ihnen besucht

Delayed Upgrade Clock